Genzyme which has struggled with manufacturing problems of its top products, said it would expand operations in Geel, Belgium, to support its drugs for Pompe disease. Genzyme, which is the target of an $18.5 billion takeover bid by France's Sanofi-Aventis, said it would build an additional manufacturing plant in Geel to support the long-term growth of its drugs, Myozyme and Lumizyme.
This interview covers key results of the study ‘Success Factor Supply Chain Management and Logistics in the Chemical Industry 2024’ by Solventure, Aimms and Miebach.
Novo Nordisk recently announced changes to its executive leadership and Board of Directors.
Honeywell will acquire Johnson Matthey's Catalyst Technologies business segment for €2.15 billion in an all-cash transaction.
Oxea is returning to its old name and its roots.
Jens Birgersson becomes new Brenntag CEO
